Nootropic peptides on TikTok: separating signal from hype

What did @b.louden06 actually say?

The creator ranked Dihexa in D tier, which is actually the most defensible part of the video. They claimed Dihexa was invented at Washington State University for Alzheimer's treatment, that it works by "allosterically amplifying HGF" to bind the c-Met receptor, and that this drives "neurogenesis and long-term brain plasticity." They also warned that Dihexa could cause "ovarian somnopathy of genesis" leading to autism, schizophrenia, and epilepsy, and suggested TAK or ACD as safer alternatives.

The transcript has some clear audio mangling, particularly "naphthogenesis" (almost certainly neurogenesis) and "ovarian somnopathy of genesis" (likely oncogenesis, meaning tumor formation). That distinction matters a lot, because misidentifying a cancer risk as some obscure condition you've never heard of is genuinely dangerous misinformation, even if accidental.

Does the science back this up?

The mechanism description is mostly accurate, even if it sounds like it was transcribed through a broken microphone. The oncogenesis risk is real, not invented, and is actually the most important thing to understand about this compound.

Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed by Joseph Harding and Henryk Motin at Washington State University. Their 2013 paper in the Journal of Pharmacology and Experimental Therapeutics (McCoy et al.) confirmed it acts as a positive allosteric modulator of hepatocyte growth factor (HGF) signaling at the c-Met receptor. In animal models, it showed cognitive enhancement roughly seven orders of magnitude more potent than BDNF. That is a striking figure, and it is why this compound got traction in nootropic circles.

The problem is that HGF/c-Met signaling is a well-documented driver of tumor growth and metastasis. Aberrant c-Met activation is implicated in lung, gastric, and hepatocellular carcinomas, among others. There are no human clinical trials for Dihexa. None. The leap from rat cognition studies to human use skips approximately a decade of safety work that has not been done.

What did they get wrong (or right)?

Credit where it is due: the WSU origin story is accurate, the mechanism summary is roughly correct, and putting Dihexa in D tier shows more restraint than most peptide influencers. The D-tier call is the right call.

But the errors here are significant. First, "ovarian somnopathy of genesis" is almost certainly "oncogenesis," and getting that wrong strips the warning of all its meaning. The oncogenesis risk is the primary reason serious researchers are not pursuing Dihexa in humans right now. Calling it something that sounds like a sleep disorder buried under jargon is the opposite of helpful.

Second, the claim that Dihexa will "amplify the person you are right now" and that scrolling all day will make it "absolutely terrible for you" is unverifiable speculation dressed up as mechanism. There is zero human data to support that kind of activity-dependent amplification narrative in people. It is compelling content, but it is not science.

Third, recommending "TAK or ACD" as alternatives without context is vague enough to be meaningless and potentially misleading depending on what those abbreviations actually refer to in context.

What should you actually know?

Dihexa has never been tested in human clinical trials. Its only evidence base is rodent studies, and the mechanism that makes it interesting for cognition, amplifying c-Met signaling, is the same mechanism that raises serious cancer concerns.

The HGF/c-Met pathway is actively being targeted by oncologists trying to inhibit it in cancer patients. That is not a minor footnote. Any compound that potently upregulates this pathway without human safety data should be treated with extreme caution. No dose of Dihexa has been established as safe in humans. The compound is not FDA-approved, not legal to sell as a supplement, and not available through legitimate compounding pharmacies for human use.

• The cognitive effects seen in rats have not been replicated in human trials because those trials do not exist.
• The oncogenesis risk is not theoretical hand-wringing. It follows directly from the compound's mechanism of action.
• Anyone selling Dihexa for human consumption is operating outside the bounds of regulated medicine.

If cognitive enhancement is the goal, there are compounds with actual human safety profiles worth discussing with a licensed provider. Dihexa is not one of them right now.